New trial
Phase 1b/2 trial: cemiplimab (PD-1 inhibitor) with investigational anti-TIM3, anti-CD73, and anti-NKG2A antibodies
- Trial ID
- NCT06162572 on ClinicalTrials.gov
- Cancer type
- NSCLC
- Location
- 73 Locations
- Published in
- New in Oncology - June 16, 2025
This multicenter, open-label study by Servier Bio-Innovation LLC evaluates cemiplimab combined with novel agents in adult patients with untreated advanced/metastatic NSCLC with high PD-L1 expression. The trial features a safety lead-in phase and randomized dose expansion to determine optimal combination dosing.
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC